Industry News

Mallinckrodt, a U.K.-based specialty pharmaceutical company. The acquisition was completed Wednesday; terms were not disclosed. But Madison-based Stratatech will continue operating in Madison and will keep all of its jobs, CEO and founder Lynn Allen-Hoffmann said, in an interview with the Wisconsin State Journal."/>
BRIEF: Stratatech acquisition becomes final; jobs will stay in Madison, CEO says [The Wisconsin State Journal]
Opko Health, Inc. has closed its acquisition of Canada-based clinical stage biotechnology company Transition Therapeutics Inc., the company said on Wednesday. Under the terms of the agreement approved by the boards of directors of both companies, Transition Therapeutics security holders will receive approximately 6.4 m shares of Opko common stock. Based on the moving average price of Opko common stock for the five trading days..."/>
Opko Health Closes USD 60m Acquisition of Biotechnology Firm Transition Therapeutics
Community Health Options, the Maine-based health insurance cooperative, continued its financial recovery in the second quarter from a staggering $31 million loss in 2015.. The insurer reported on Wednesday a net loss of $3.3 million in the second quarter, down from a loss of $8.4 million in the first quarter. As of June 30, Community Health had $45.6 million remaining in reserves from premiums, borrowing, investments and other sources."/>
Community Health Options continues to recover from $31 million loss in 2015 [Portland Press Herald, Maine]
American Renal Associates Holdings, Inc.. Investors who purchased or otherwise acquired shares 1) pursuant and/or traceable to the Initial Public Offering (“ IPO”) on or about April 21, 2016; and/or 2) on the open market between April 21, 2016 and August 18, 2016 (the“ Class Period”), are encouraged to contact the Firm in advance of the October 31, 2016 lead plaintiff motion deadline.."/>
INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against American Renal Associates Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
PAREXEL International Corporation concerning possible violations of federal securities laws. If you purchased or otherwise acquired PAREXEL shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you."/>
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against PAREXEL International Corporation and Advises Investors With Losses to Contact the Firm
Coherus BioSciences, Inc., today announced that effective August 31, 2016, the compensation committee of the company’ s board of directors granted 6 new employees options to purchase an aggregate of 80,000 shares of the company’ s common stock with a per share exercise price of $29.77, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan,..."/>
Coherus BioSciences Announces New Employment Inducement Grants
HMS Holdings Corp today announced that Jeff Sherman, Chief Financial Officer, will be participating in a“ fireside chat” at the Baird 2016 Global Healthcare Conference at 9:40 am ET/ 8:40am CT on September 7, 2016 at The New York Palace Hotel. A link to the audiocast will be available on the Company's website at cfm. HMS Holdings Corp., through its subsidiaries, provides coordination of benefits and payment integrity..."/>
HMS to Present at the Baird 2016 Global Healthcare Conference
Cynapsus Therapeutics Inc. today announced that the companies have signed a definitive agreement under which Sunovion will acquire Cynapsus for US $40.50 per share..."/>
Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics
Invacare Corporation today announced its conference schedule for September 2016.. On Tuesday, September 13, at 12:30 p.m., Matthew E. Monaghan, Chairman, President and Chief Executive Officer, will present at CL King’ s 14th Annual Best Ideas Conference at the Omni Berkshire Place Hotel in New York. The live webcast of the presentation will be available at, and it will be accessible for replay for 90 days following the conference."/>
Invacare Corporation to Present at September 2016 Conferences
AstraZeneca today announced results from the SYMBICORT ® Inhalation Aerosol LABA safety study showing patients with controlled and uncontrolled asthma had a comparable risk of serious asthma-related events and a lower risk of asthma exacerbations when formoterol was combined with budesonide versus budesonide alone. The study compared the..."/>
AstraZeneca Announces SYMBICORT Demonstrated Comparable Risk of Serious Asthma-Related Events and Lower Risk of Asthma Exacerbations Compared to Budesonide Alone
Mallinckrodt plc, a leading specialty pharmaceutical company, today announced it closed the acquisition of Stratatech Corporation, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products. Developmental products include StrataGraft ® regenerative skin tissue and a technology platform for genetically enhanced skin tissues. Under Mallinckrodt's..."/>
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products
iKang Healthcare Group, Inc., the largest provider in China’ s fast growing private preventive healthcare services market with a market share of 13.6% in terms of revenue in calendar year 2014, today announced its unaudited financial results for the first quarter ended June 30, 2016.. Fiscal First Quarter Ended June 30, 2016 Financial Highlights. Net revenues were US $101.2 million, an increase of 17.3% year-over-year Gross profit was US $44.7 million, an..."/>
IKang Announces Unaudited Financial Results for the First Quarter Ended June 30, 2016
Nightingale Informatix Corporation today announced the voting results from the Special Meeting of Shareholders held on August 30, 2016 in Toronto, Ontario. Nightingale announced that the Company's shareholders have voted in favour of all items of business at the Meeting, which was comprised of:. a special resolution authorizing and approving the sale of substantially all of the assets of the Company in accordance with Section 184 of the Business..."/>
Nightingale Announces the Results of Shareholder Vote
MRI Interventions, Inc. today announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds to MRI Interventions of approximately $4.25 million, before deducting placement agents’ fees and estimated offering expenses. The securities under the securities purchase agreement consist of 851,000 units, composed of an aggregate of approximately 851,000 shares of its common..."/>
MRI Interventions Announces $6 Million Private Placement
Oncobiologics, Inc., a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody biosimilar therapeutics, today announced that its Chairman, CEO and President, Pankaj Mohan, Ph.D., will present at the BioCentury’ s Annual NewsMakers in the Biotech Industry Conference. The presentation will take place on Friday, September 9, 2016 at 2:30 p.m. ET in room 402/ 403 of the..."/>
Oncobiologics to Present at BioCentury’s NewsMakers in the Biotech Industry Conference
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced the completion of a secured debt offering of $40 million. Egalet plans to use the net proceeds from this transaction to repay all outstanding obligations to Hercules Capital, Inc. under its existing loan agreement, to support the approval and..."/>
Egalet Completes $40 Million Secured Debt Financing
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will provide a corporate overview, including an update on the status of the Company’ s necuparanib program, at the 2016 Wells Fargo Healthcare Conference in Boston, MA. The presentation is scheduled to begin on Wednesday, September 7 th at 1:45 p.m. ET.. The audio webcast of the presentation will be..."/>
Momenta Pharmaceuticals to Webcast Presentation at the 2016 Wells Fargo Healthcare Conference
HCA Holdings, Inc. is scheduled to present at the following healthcare conferences in September 2016.. September 8, 2016 at 10:15 a.m. at the Baird 2016 Global Healthcare Conference held at The New York Palace, New York, NY. September 14, 2016 at 10:30 a.m. at the Morgan Stanley Global Healthcare Conference held at the Grand Hyatt New York, New York, NY."/>
HCA to Present at September Healthcare Conferences
Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will be presenting at the Baird 2016 Global Healthcare Conference on September 7 at 10:50 a.m. EDT. A simultaneous webcast can be accessed by visiting the Investors section of and selecting Events and Presentations. A replay will be available for 30 days following the..."/>
Axovant Sciences to Present at the Baird 2016 Global Healthcare Conference
Quorum Health Corporation today announced that management will participate in the following conferences in September 2016:. September 7, 2016, at 8:45 a.m. at the Wells Fargo 2016 Healthcare Conference held at The Westin Boston Waterfront, Boston, MA. September 8, 2016, at 11:25 a.m. at the Baird 2016 Healthcare Conference held at The New York Palace, New York, NY."/>
Quorum Health Corporation to Participate in Two September Healthcare Conferences

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary641 Articles
Information Technology617 Articles
Financials494 Articles
Industrials393 Articles
Health Care374 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at